ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2257

Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial

Adam Taylor1, Lang Chen 1, Ronan O'Beirne 2, Joshua Melnick 3, Eric Ruderman 4, Jeffrey Curtis 1 and Maria Danila 1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3University of Alabama at Birmingham, Birmimgham, AL, 4Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Behavioral strategies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The treat to target (T2T) treatment strategy is associated with better clinical outcomes in patients with rheumatoid arthritis (RA). We have previously found that a direct-to-patient video intervention aimed to increase knowledge about T2T was associated with increased willingness to adopt RA treatment. The goal of this study was to evaluate patient and clinical characteristics associated with improved willingness to adopt treatment.

Methods: The CONTROL-RA trial, as previously reported, enrolled participants with self-reported RA, with RAPID 3 >4 (range 0-10) and without potentially confounding conditions or who had been using disease modifying anti-rheumatic drugs (DMARDs) in the past 6 months. Outcomes were collected using compensated surveys. Participants completed a baseline survey, viewed the educational intervention and completed the follow up survey immediately after. Intervention group participants viewed up to 6 videos (minimum of 2, mean duration 2 min) on topics relevant to T2T. We performed a multivariate analysis, where the primary outcome was pre-post difference in patient-reported willingness to adopt treatment. The following factors were considered: extent of engagement (e.g. high engagement group watched >80% of each of the 6 videos vs low engagement group watched less), age, sex, race, prior biologic/DMARD use, general health, health literacy, familiarity with T2T, patient global assessment, patient acceptable symptom state (PASS), decision conflict about treatment change (decision conflict scale, lower score is better), readiness for treatment change (precaution adoption process model) and personal attitudes favoring medications (10 items surveying patient attitudes regarding acceptable medication risks vs benefits; higher score is more favorable).

Results: Responses of 104 participants in the intervention group were analyzed (Table 1). Participants were 92% white, 92% women, with a mean age of 49 years. A total of 80 (77%) participants were classified in the high engagement group. Participants classified in the high engagement group had higher baseline willingness to adopt treatment than those in the low engagement group (7.1 vs 5.5, p=0.006). The pre-post difference in willingness to adopt treatment was 0.6 in the high engagement group and 0.3 in the low engagement group (p = 0.57). In multivariable models the level of engagement with the intervention was not associated with improved willingness to adopt treatment (p=0.14). Lower baseline level of willingness to change RA treatment, older age and personal attitudes favoring medications were associated with improved willingness to adopt RA treatment (Table 2).

Conclusion: We observed a high level of engagement and were thus not able to discern a dose-response relationship between our intervention and improved willingness after the intervention. Interestingly, those with higher willingness to change treatment were more likely to view the educational intervention, suggesting that those who are less open to treatment change may need additional support to get involved with this type of educational program.


Table 1.


Disclosure: A. Taylor, None; L. Chen, None; R. O'Beirne, None; J. Melnick, None; E. Ruderman, Pfizer, 2; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; M. Danila, Pfizer, 2, Sanofi Regeneron, 5.

To cite this abstract in AMA style:

Taylor A, Chen L, O'Beirne R, Melnick J, Ruderman E, Curtis J, Danila M. Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patient-and-clinical-characteristics-associated-with-increased-willingness-to-adopt-ra-treatment-after-an-educational-intervention-an-analysis-of-the-confident-treatment-decisions-for-living-with-rhe/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-clinical-characteristics-associated-with-increased-willingness-to-adopt-ra-treatment-after-an-educational-intervention-an-analysis-of-the-confident-treatment-decisions-for-living-with-rhe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology